TRAIL modulates the immune system and protects against the development of diabetes

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Bossi, Fleur ^a   Bernardi, Stella ^a   Zauli, Giorgio ^b   Secchiero, Paola ^c   Fabris, Bruno ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; DISEASE COURSE; DRUG MECHANISM; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ANIMAL; DIABETES MELLITUS; GENETICS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS; HUMANS; IMMUNE SYSTEM; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION;

EID: 84924230640     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/680749     Document Type: Article

References (105)

1. S. Bernardi, P. Secchiero, and G. Zauli, "State of art and recent developments of anti-cancer strategies based on TRAIL," Recent Patents on Anti-Cancer Drug Discovery, vol. 7, no. 2, pp. 207-217, 2012.
2. S. R. Wiley, K. Schooley, P. J. Smolak et al. , "Identification and characterization of a new member of the TNF family that induces apoptosis," Immunity, vol. 3, no. 6, pp. 673-682, 1995.
3. V. Nikoletopoulou, M. Markaki, K. Palikaras, and N. Tavernarakis, "Crosstalk between apoptosis, necrosis and autophagy," Biochimica et Biophysica Acta, vol. 1833, no. 12, pp. 3448-3459, 2013.
4. S. Jouan-Lanhouet, M. I. Arshad, C. Piquet-Pellorce et al. , "TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation," Cell Death and Differentiation, vol. 19, no. 12, pp. 2003-2014, 2012.
5. G. Pan, K. O'Rourke, A. M. Chinnaiyan et al. , "The receptor for the cytotoxic ligand TRAIL," Science, vol. 276, no. 5309, pp. 111-113, 1997.
6. G. Pan, J. Ni, Y.-F. Wei, G.-I. Yu, R. Gentz, and V. M. Dixit, "An antagonist decoy receptor and a death domain-containing receptor for TRAIL," Science, vol. 277, no. 5327, pp. 815-818, 1997.
7. J. P. Sheridan, S. A. Marsters, R. M. Pitti et al. , "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors," Science, vol. 277, no. 5327, pp. 818-821, 1997.
8. G. S. Wu, T. F. Burns, E. R. McDonald III et al. , "KILLER/DR5 is aDNA damage-inducible p53-regulated death receptor gene," Nature Genetics, vol. 17, no. 2, pp. 141-143, 1997.
9. D. Milani, G. Zauli, E. Rimondi et al. , "Tumour necrosis factorrelated apoptosis-inducing ligand sequentially activates prosurvival and pro-apoptotic pathways in SK-N-MC neuronal cells," Journal ofNeurochemistry, vol. 86,no. 1, pp. 126-135, 2003.
10. M. A. Degli-Esposti, P. J. Smolak, H. Walczak et al. , "Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family," The Journal of Experimental Medicine, vol. 186, no. 7, pp. 1165-1170, 1997.
11. M. A. Degli-Esposti,W. C. Dougall, P. J. Smolak, J. Y. Waugh, C. A. Smith, and R. G. Goodwin, "The novel receptor TRAIL-R4 induces NF-B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain," Immunity, vol. 7, no. 6, pp. 813-820, 1997.
12. S. A. Marsters, J. P. Sheridan, R. M. Pitti et al. , "A novel receptor for Apo2L/TRAIL contains a truncated death domain," Current Biology, vol. 7, no. 12, pp. 1003-1006, 1997.
13. G. Zauli, E. Melloni, S. Capitani, and P. Secchiero, "Role of fulllength osteoprotegerin in tumor cell biology," Cellular and Molecular Life Sciences, vol. 66, no. 5, pp. 841-851, 2009.
14. E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J. J. Peschon, and M. J. Smyth, "Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice," Journal of Immunology, vol. 168, no. 3, pp. 1356-1361, 2002.
15. L. M. Sedger, M. B. Glaccum, J. C. Schuh et al. , "Characterization of the in vivo function of TNF-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice," European Journal of Immunology, vol. 32, no. 8, pp. 2246-2254, 2002.
16. E. M. Janssen, N. M. Droin, E. E. Lemmens et al. , "CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death," Nature, vol. 434, no. 7029, pp. 88-93, 2005.
17. K. Takeda,M. J. Smyth, E. Cretney et al. , "Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development," The Journal of Experimental Medicine, vol. 195, no. 2, pp. 161-169, 2002.
18. N. D. Huntington, C. A. J. Vosshenrich, and J. P. di Santo, "Developmental pathways that generate natural-killer-cell diversity in mice and humans," Nature Reviews Immunology, vol. 7, no. 9, pp. 703-714, 2007.
19. S. Nagata, "Apoptosis by death factor," Cell, vol. 88, no. 3, pp. 355-365, 1997.
20. L. A. Tartaglia and D. V. Goeddel, "Two TNF receptors," Immunology Today, vol. 13, no. 5, pp. 151-153, 1992.
21. A. Ashkenazi andR. S. Herbst, "To kill a tumor cell: the potential of proapoptotic receptor agonists," The Journal of Clinical Investigation, vol. 118, no. 6, pp. 1979-1990, 2008.
22. A. Ashkenazi, R. C. Pai, S. Fong et al. , "Safety and antitumor activity of recombinant soluble Apo2 ligand," The Journal of Clinical Investigation, vol. 104, no. 2, pp. 155-162, 1999.
23. M. Leverkus, H. Walczak, A. McLellan et al. , "Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligandmediated apoptosis," Blood, vol. 96, no. 7, pp. 2628-2631, 2000.
24. P. Secchiero, A. Gonelli, E. Carnevale et al. , "TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways," Circulation, vol. 107, no. 17, pp. 2250-2256, 2003.
25. G. Zauli, S. Sancilio, A. Cataldi, N. Sabatini, D. Bosco, and R. Di Pietro, "PI-3K/Akt and NF-B/IB pathways are activated in Jurkat T cells in response to TRAIL treatment," Journal of Cellular Physiology, vol. 202, no. 3, pp. 900-911, 2005.
26. I. Hunter and G. F. Nixon, "Spatial compartmentalization of tumor necrosis factor (TNF) receptor 1-dependent signaling pathways in human airway smooth muscle cells: lipid rafts are essential for TNF-mediated activation of RhoA but dispensable for the activation of the NF-B and MAPK pathways," The Journal of Biological Chemistry, vol. 281, no. 45, pp. 34705-34715, 2006.
27. J. H. Song, M. C. L. Tse, A. Bellail et al. , "Lipid rafts and nonrafts mediate tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic and nonapoptotic signals in nonsmall cell lung carcinoma cells," Cancer Research, vol. 67, no. 14, pp. 6946-6955, 2007.
28. B. Toffoli, S. Bernardi, R. Candido, S. Zacchigna, B. Fabris, and P. Secchiero, "TRAIL shows potential cardioprotective activity," Investigational New Drugs, vol. 30, no. 3, pp. 1257-1260, 2012.
29. L. M. Sedger, A. Katewa, A. K. Pettersen et al. , "Extreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL and TRAIL double-deficient mice," Blood, vol. 115, no. 16, pp. 3258-3268, 2010.
30. S.-E. Lamhamedi-Cherradi, S.-J. Zheng, K. A. Maguschak, J. Peschon, and Y. H. Chen, "Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL/mice," Nature Immunology, vol. 4, no. 3, pp. 255-260, 2003.
31. E. Cretney, A. P. Uldrich, S. P. Berzins, A. Strasser,D. I. Godfrey, and M. J. Smyth, "Normal thymocyte negative selection in TRAIL-deficient mice," The Journal of Experimental Medicine, vol. 198, no. 3, pp. 491-496, 2003.
32. C. M. Walsh, B. G. Wen, A. M. Chinnaiyan, K. O'Rourke, V. M. Dixit, and S. M. Hedrick, "A role for FADD in T cell activation and development," Immunity, vol. 8, no. 4, pp. 439-449, 1998.
33. N. Corazza, G. Brumatti, S. Jakob, A. Villunger, and T. Brunner, "TRAIL and thymocyte apoptosis: not so deadly" Cell Death and Differentiation, vol. 11, no. 2, pp. S213-S215, 2004.
34. S. A. Marsters, R. M. Pitti, C. J. Donahue, S. Ruppert, K. D. Bauer, and A. Ashkenazi, "Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA," Current Biology, vol. 6, no. 6, pp. 750-752, 1996.
35. M. J. Martńez-Lorenzo,M. A. Alava, S. Gamen et al. , "Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells," European Journal of Immunology, vol. 28, no. 9, pp. 2714-2725, 1998.
36. T. Ikeda, S. Hirata, S. Fukushima et al. , "Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells," Journal of Immunology, vol. 185, no. 9, pp. 5259-5267, 2010.
37. S. H. Wang, G. H. Chen,Y. Fan,M. VanAntwerp, andJ. R. Baker Jr. , "Tumor necrosis factor-related apoptosis-inducing ligand inhibits experimental autoimmune thyroiditis by the expansion of CD4+CD25+ regulatory T cells," Endocrinology, vol. 150, no. 4, pp. 2000-2007, 2009.
38. S. Sakaguchi, F. Powrie, and R. M. Ransohoff, "Re-establishing immunological self-tolerance in autoimmune disease," Nature Medicine, vol. 18, no. 1, pp. 54-58, 2012.
39. C. Lehnert, M. Weiswange, I. Jeremias et al. , "TRAIL-receptor costimulation inhibits proximal TCR signaling and suppresses human T cell activation and proliferation," The Journal of Immunology, vol. 193, no. 8, pp. 4021-4031, 2014.
40. K. Song, Y. Chen, R. Göke et al. , "Tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression," Journal of Experimental Medicine, vol. 191, no. 7, pp. 1095-1103, 2000.
41. X. R. Zhang, L. Y. Zhang, S. Devadas, L. Li, A. D. Keegan, and Y. F. Shi, "Reciprocal expression of TRAIL and CD95L in Th1 and Th2 cells: role of apoptosis in T helper subset differentiation," Cell Death & Differentiation, vol. 10, no. 2, pp. 203-210, 2003.
42. A. I. Roberts, S. Devadas, X. Zhang et al. , "The role of activation-induced cell death in the differentiation of T-helper-cell subsets," Immunologic Research, vol. 28,no. 3, pp. 285-293, 2003.
43. A. Bosque, J. Pardo, M. J. Martńez-Lorenzo et al. , "Human CD8+ T cell blasts are more sensitive than CD4+ T cell blasts to regulation by APO2L/TRAIL," European Journal of Immunology, vol. 35, no. 6, pp. 1812-1821, 2005.
44. A. Bosque, J. I. Aguiló, M. Del Rey et al. , "Cell cycle regulation by FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymphoproliferative syndromes," Journal of Leukocyte Biology, vol. 84, no. 2, pp. 488-498, 2008.
45. J. D. Lünemann, S. Waiczies, S. Ehrlich et al. , "Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells," Journal of Immunology, vol. 168, no. 10, pp. 4881-4888, 2002.
46. J. Ursini-Siegel, W. Zhang, A. Altmeyer et al. , "Trail/Apo-2 ligand induces primary plasma cell apoptosis," The Journal of Immunology, vol. 169, no. 10, pp. 5505-5513, 2002.
47. N. Kayagaki, N. Yamaguchi,M. Abe et al. , "Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL)," Cellular Immunology, vol. 219, no. 2, pp. 82-91, 2002.
48. S. A. Renshaw, J. S. Parmar, V. Singleton et al. , "Acceleration of human neutrophil apoptosis by TRAIL," Journal of Immunology, vol. 170, no. 2, pp. 1027-1033, 2003.
49. S. Bernardi, D. Milani, B. Fabris, P. Secchiero, and G. Zauli, "TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases," Current Drug Targets, vol. 13, no. 9, pp. 1215-1221, 2012.
50. R. Ross, "Atherosclerosis-an inflammatory disease," The New England Journal of Medicine, vol. 340, no. 2, pp. 115-126, 1999.
51. P. Secchiero, F. Corallini, M. G. Di Iasio, A. Gonelli, E. Barbarotto, and G. Zauli, "TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by downmodulating CCL8 and CXCL10 chemokine expression and release," Blood, vol. 105, no. 9, pp. 3413-3419, 2005.
52. P. Secchiero, R. Candido, F. Corallini et al. , "Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice," Circulation, vol. 114, no. 14, pp. 1522-1530, 2006.
53. B. A. Di Bartolo, J. Chan, M. R. Bennett et al. , "TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe/mice," Diabetologia, vol. 54, no. 12, pp. 3157-3167, 2011.
54. P. J. Roberts-Thomson, M. W. Jackson, and T. P. Gordon, "A seminal monograph: Mackay and Burnet's Autoimmune diseases," Medical Journal of Australia, vol. 196, no. 1, pp. 74-76, 2012.
55. J. Diana, Y. Simoni, L. Furio et al. , "Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes," Nature Medicine, vol. 19,no. 1, pp. 65-73, 2013.
56. K. Koczwara, E. Bonifacio, and A.-G. Ziegler, "Transmission of maternal islet antibodies and risk of autoimmune diabetes in offspring of mothers with type 1 diabetes," Diabetes, vol. 53, no. 1, pp. 1-4, 2004.
57. T. P. Di Lorenzo, M. Peakman, and B. O. Roep, "Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes," Clinical & Experimental Immunology, vol. 148, no. 1, pp. 1-16, 2007.
58. E. E. Hamilton-Williams, S. E. Palmer, B. Charlton, and R. M. Slattery, "Beta cell MHC class I is a late requirement for diabetes," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6688-6693, 2003.
59. K. Buschard, S. Madsbad, and J. Rygaard, "Depressed suppressor cell activity in patients with newly diagnosed insulindependent diabetes mellitus," Clinical and Experimental Immunology, vol. 41, no. 1, pp. 25-32, 1980.
60. M.-G. Roncarolo and M. Battaglia, "Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans," Nature Reviews Immunology, vol. 7, no. 8, pp. 585-598, 2007.
61. B. O. Roep, "The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure," Diabetologia, vol. 46, no. 3, pp. 305-321, 2003.
62. G. S. Eisenbarth, "Type I diabetes mellitus. A chronic autoimmune disease," The New England Journal of Medicine, vol. 314, no. 21, pp. 1360-1368, 1986.
63. S. Martin, D. Wolf-Eichbaum, G. Duinkerken et al. , "Development of type 1 diabetes despite severe hereditary B-cell deficiency," The New England Journal of Medicine, vol. 345, no. 14, pp. 1036-1040, 2001.
64. T. L. van Belle, K. T. Coppieters, and M. G. vonHerrath, "Type 1 diabetes: etiology, immunology, and therapeutic strategies," Physiological Reviews, vol. 91, no. 1, pp. 79-118, 2011.
65. S. Bernardi, A. Norcio, B. Toffoli, G. Zauli, and P. Secchiero, "Potential role of TRAIL in the management of autoimmune diabetes mellitus," Current Pharmaceutical Design, vol. 18, no. 35, pp. 5759-5765, 2012.
66. S. E. Lamhamedi-Cherradi, S. Zheng, R. M. Tisch, and Y. H. Chen, "Critical roles of tumor necrosis factor-related apoptosisinducing ligand in type 1 diabetes," Diabetes, vol. 52, no. 9, pp. 2274-2278, 2003.
67. G. Zauli, B. Toffoli, M. G. Di Iasio, C. Celeghini, B. Fabris, and P. Secchiero, "Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes," Diabetes, vol. 59, no. 5, pp. 1261-1265, 2010.
68. G. Tornese, D. Iafusco, L. Monasta et al. , "The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement," Acta Diabetologica, vol. 51, no. 2, pp. 239-246, 2014.
69. Q.-S. Mi, D. Ly, S.-E. Lamhamedi-Cherradi et al. , "Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice," Diabetes, vol. 52, no. 8, pp. 1967-1975, 2003.
70. L. J. Appleman, D. Tzachanis, T. Grader-Beck, A. A. F. L. van Puijenbroek, and V. A. Boussiotis, "Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics," Journal ofMolecularMedicine, vol. 78,no. 12, pp. 673-683, 2000.
71. S. Kang, S.-Y. Park, H.-J. Lee, and Y. H. Yoo, "TRAIL upregulates decoy receptor 1 andmediates resistance to apoptosis in insulinsecreting INS-1 cells," Biochemical and Biophysical Research Communications, vol. 396, no. 3, pp. 731-735, 2010.
72. E. Dirice, S. Kahraman, G. O. Elpek et al. , "TRAIL and DcR1 expressions are differentially regulated in the pancreatic islets of STZ-versus CY-applied NOD mice," Experimental Diabetes Research, vol. 2011, Article ID 625813, 11 pages, 2011.
73. S. Kang, E.-J. Park, Y. Joe et al. , "Systemic delivery of TNFRelated Apoptosis-Inducing Ligand (TRAIL) elevates levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and prevents type 1 diabetes in nonobese diabetic mice," Endocrinology, vol. 151, no. 12, pp. 5638-5646, 2010.
74. P. R. Maxwell, P. M. Timms, S. Chandran, and D. Gordon, "Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with Type 1 diabetes," DiabeticMedicine, vol. 18, no. 10, pp. 777-780, 2001.
75. F. J. Descamps, E. Martens, F. Ballaux, K. Geboes, andG. Opdenakker, "In vivo activation of gelatinase B/MMP-9 by trypsin in acute pancreatitis is a permissive factor in streptozotocininduced diabetes," Journal of Pathology, vol. 204, no. 5, pp. 555-561, 2004.
76. M. Xue, P. J. Thompson, R. Clifton-Bligh, G. Fulcher, E. D. M. Gallery, and C. Jackson, "Leukocyte matrix metalloproteinase-9 is elevated and contributes to lymphocyte activation in type I diabetes," International Journal of Biochemistry and Cell Biology, vol. 37, no. 11, pp. 2406-2416, 2005.
77. X. Han, Y. Sun, S. Scott, and D. Bleich, "Tissue inhibitor of metalloproteinase-1 prevents cytokine-mediated dysfunction and cytotoxicity in pancreatic islets and-cells," Diabetes, vol. 50, no. 5, pp. 1047-1055, 2001.
78. R. A. Defronzo, "Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus," Diabetes, vol. 58, no. 4, pp. 773-795, 2009.
79. W. Ebstein, "Zur therapie des diabetes mellitus, insbesondere uber die Anwendung des salicylsauren natron bei demselben," Berliner KlinischeWochenschrift, vol. 13, pp. 337-340, 1876.
80. J. C. Pickup and M. A. Crook, "Is type II diabetes mellitus a disease of the innate immune system" Diabetologia, vol. 41, no. 10, pp. 1241-1248, 1998.
81. W. Yang, J. Lu, J. Weng et al. , "Prevalence of diabetes among men and women in China," The New England Journal of Medicine, vol. 362, no. 12, pp. 1090-1101, 2010.
82. P. A. Tataranni and E. Ortega, "A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes" Diabetes, vol. 54, no. 4, pp. 917-927, 2005.
83. G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, "Adipose expression of tumor necrosis factor-: direct role in obesity-linked insulin resistance," Science, vol. 259, no. 5091, pp. 87-91, 1993.
84. G. S. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M. F. White, and B. M. Spiegelman, "IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity inTNF-and obesity-induced insulin resistance," Science, vol. 271, no. 5249, pp. 665-668, 1996.
85. M. Visser, L. M. Bouter, G. M. McQuillan, M. H. Wener, and T. B. Harris, "Elevated C-reactive protein levels in overweight and obese adults," The Journal of the American Medical Association, vol. 282, no. 22, pp. 2131-2135, 1999.
86. D. J. Freeman, J. Norrie, M. J. Caslake et al. , "C-reactive protein is an independent predictor of risk for the development of diabetes in the west of Scotland coronary prevention study," Diabetes, vol. 51, no. 5, pp. 1596-1600, 2002.
87. F. B. Hu, J. B. Meigs, T. Y. Li, N. Rifai, and J. E. Manson, "Inflammatorymarkers and risk of developing type 2 diabetes in women," Diabetes, vol. 53, no. 3, pp. 693-700, 2004.
88. S. Bernardi, B. Fabris, M. Thomas et al. , "Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes," Molecular and Cellular Endocrinology, vol. 394, no. 1-2, pp. 13-20, 2014.
89. H. Sell, C. Habich, and J. Eckel, "Adaptive immunity in obesity and insulin resistance,"Nature Reviews Endocrinology, vol. 8, no. 12, pp. 709-716, 2012.
90. S. Cinti, G. Mitchell, G. Barbatelli et al. , "Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans," Journal of Lipid Research, vol. 46, no. 11, pp. 2347-2355, 2005.
91. K. J. Strissel, Z. Stancheva, H. Miyoshi et al. , "Adipocyte death, adipose tissue remodeling, and obesity complications," Diabetes, vol. 56, no. 12, pp. 2910-2918, 2007.
92. S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante Jr. , "Obesity is associated with macrophage accumulation in adipose tissue," Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796-1808, 2003.
93. R. S. Lindsay, D. J. Wake, S. Nair et al. , "Subcutaneous adipose 11-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians," The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 6, pp. 2738-2744, 2003.
94. H. Masuzaki, J. Paterson, H. Shinyama et al. , "A transgenic model of visceral obesity and themetabolic syndrome," Science, vol. 294, no. 5549, pp. 2166-2170, 2001.
95. H. Xu, G. T. Barnes, Q. Yang et al. , "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance,"The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1821-1830, 2003.
96. J. I. Odegaard and A. Chawla, "Connecting type 1 and type 2 diabetes through innate immunity," Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 3,Article ID a007724, 2012.
97. S. P. Weisberg, D. Hunter, R. Huber et al. , "CCR2 modulates inflammatory andmetabolic effects of high-fat feeding," Journal of Clinical Investigation, vol. 116, no. 1, pp. 115-124, 2006.
98. H. Kanda, S. Tateya, Y. Tamori et al. , "MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity,"The Journal of Clinical Investigation, vol. 116, no. 6, pp. 1494-1505, 2006.
99. S. Winer, Y. Chan, G. Paltser et al. , "Normalization of obesityassociated insulin resistance through immunotherapy," Nature Medicine, vol. 15, no. 8, pp. 921-929, 2009.
100. M. Saberi, N.-B. Woods, C. de Luca et al. , "Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice," Cell Metabolism, vol. 10, no. 5, pp. 419-429, 2009.
101. S. Bernardi, G. Zauli, C. Tikellis et al. , "TNF-related apoptosisinducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation," Clinical Science (London, England : 1979), vol. 123, no. 9, pp. 547-555, 2012.
102. S. Bernardi, C. Tikellis, R. Candido et al. , "ACE2 deficiency shifts energy metabolism towards glucose utilization," Metabolism, vol. 64, no. 3, pp. 406-415, 2015.
103. B. Toffoli, S. Bernardi, R. Candido et al. , "Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets,"Molecular andCellular Endocrinology, vol. 331, no. 1, pp. 136-142, 2011.
104. C. Pitombo, E. P. Araújo, C. T. De Souza, J. C. Pareja, B. Geloneze, and L. A. Velloso, "Amelioration of diet-induced diabetes mellitus by removal of visceral fat," Journal of Endocrinology, vol. 191, no. 3, pp. 699-706, 2006.
105. H. H. Harith, M. J. Morris, andM. M. Kavurma, "On the TRAIL of obesity and diabetes," Trends in Endocrinology and Metabolism, vol. 24, no. 11, pp. 578-587, 2013.